DGAP-News: Immunic, Inc.
/ Key word(s): Conference
Immunic, Inc. to Participate in Investor and Scientific Conferences in November NEW YORK, November 10, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the following investor and scientific conferences in November: - November 16-18: Stifel 2020 Virtual Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview on Tuesday, November 17, at 10:40 am ET. A live audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference. - November 17-18: Crohn's & Colitis Foundation's IBD INNOVATE: Product Development for Crohn's & Colitis Conference. Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will attend this virtual conference. About Immunic, Inc. Cautionary Statement Regarding Forward-Looking Statements Contact Information US IR Contact US Media Contact 10.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1146841 10.11.2020